End stage renal disease (ESRD) is a condition that metabolic disorders play an critical role in body physiology. The effect of omega-3 fatty acids is well documented in some inflammatory diseases via eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) components of fish oil. The aim of this study was to investigate the effects of dietary omega-3 fatty acid supplementation on levels of lipid profile and blood pressure in ESRD patients. In this study, 90 patients arrived if they are on chronic ambulatory peritoneal dialysis for 3 months, clinically stable without serious disease and in stage 1 hypertension. If patient have chronic diarrhea, malignancy, thrombocytopenia(less than 100000/mm3, coagulation disorders, need to anticoagulant drugs or psychosomatic disorders exclude from study. Group 1 (45 patients) using omega 3 capsuls, 1000mg, manufactured by Zahravi Pharmaceutical, 3 times a day for 6 weeks. Group 2 (45 patients) using placebo capsules, manufactured by Zahravi pharmaceutical, 3 times a day for 6 weeks. Serum level of total cholestrol, triglycerid, high- density lipoprotein and systolic and diastolic blood pressure are measured at begining and end of the study